Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
93Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.17M | $-2.09 |
| 2024 | $0.00 | $-29.02M | $-4.91 |
| 2023 | $0.00 | $-23.86M | $-16.99 |
| 2022 | $0.00 | $-39.52M | $-61.20 |
| 2021 | $0.00 | $-40.71M | $-67.80 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.39 per share
Typical surprise +7.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.35 vs $-0.38beat
- Wed, May 13$-0.35 vs $-0.47beat
- Wed, Feb 11$-0.41 vs $-0.34miss
- Wed, Nov 12$-0.37 vs $-0.54beat
- Wed, Aug 13$-0.78 vs $-0.53miss
- Wed, May 14$-0.70 vs $-0.80beat
Estimates and results for PYPD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
PYPDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsseekingalpha.com·3d ago·Positive
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Negative
PolyPid Q2 Earnings Call Highlights PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
View source ↗